Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain
Ended Project Grant Awarded Last action
- Award ID
- R43CA233371
- Recipient
-
Eicosis LLC UEI EM8CCFVCTV69
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $264,216
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Funding
-
- $265,542.88 Federal
- -$1,326.56 Non-federal
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- Place of performance
- Davis, CA, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$1,327 | $0 | |
| Amendment | -$1,327 | -$1,327 | |
| Amendment | $0 | $0 | |
| Original award | $268,196 | $0 |
Quick answers
Who received award R43CA233371?
R43CA233371 was awarded to Eicosis LLC by National Cancer Institute (National Institutes of Health) on September 25, 2019.
How much is award R43CA233371 worth?
$264,216 has been obligated on R43CA233371: $265,543 in federal funding and -$1,327 in non-federal funding.
Which agency awarded R43CA233371?
National Cancer Institute (National Institutes of Health) awarded R43CA233371, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award